A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs AK 002 (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions
- Sponsors Allakos
- 21 Dec 2016 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.
- 21 Dec 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.
- 26 Sep 2016 Status changed from not yet recruiting to recruiting, as reported in an Allakos media release.